High cystatin C levels predict long-term mortality in patients with ST-segment elevation myocardial infarction undergoing late percutaneous coronary intervention: A retrospective study.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
May 2019
Historique:
received: 19 12 2018
revised: 16 03 2019
accepted: 22 03 2019
pubmed: 25 3 2019
medline: 19 12 2019
entrez: 26 3 2019
Statut: ppublish

Résumé

Late percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), defined as time of PCI > 7 days from symptom onset, is a common practice with clinical benefits. This study aimed to evaluate the predictive value of admission cystatin C (cys C) level on long-term mortality in STEMI patients receiving late PCI. Medical records of STEMI patients who were hospitalized between 2009 and 2011 from eight PCI-capable hospitals in Northwest China were retrospectively analyzed. Cys C level ≥ 1.105 mg/L was considered as the best predictor of long-term mortality based on the receiver-operating characteristic analysis. Patients were followed up by phone or face-to-face interviews, and the long-term mortality was obtained by reviewing medical records. The final analysis included 716 STEMI patients who received late PCI and had available cys C levels prior to PCI, and 524 were assigned into the high cys C group and 192 the low cys C group. Patients were followed up for an average length of 40.37 months. Compared with the low cys C group, the high cys C group had a higher long-term all-cause mortality (10.4% vs 2.9%, P < 0.001) and a higher cardiac mortality (6.8% vs 2.1%, P = 0.004). Multivariate Cox regression analysis showed that high cys C level was an independent predictor for both long-term all-cause mortality and cardiac mortality. High cys C level at admission is an independent predictor of long-term mortality in STEMI patients undergoing late PCI.

Identifiants

pubmed: 30907012
doi: 10.1002/clc.23179
pmc: PMC6523002
doi:

Substances chimiques

Biomarkers 0
CST3 protein, human 0
Cystatin C 0

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-578

Informations de copyright

© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

Références

Eur Heart J. 2010 Mar;31(6):703-11
pubmed: 20037146
Eur Heart J. 2012 Oct;33(20):2569-619
pubmed: 22922416
J Crit Care. 2013 Oct;28(5):882.e13-20
pubmed: 23683571
J Am Coll Cardiol. 2009 Jul 21;54(4):281-92
pubmed: 19608025
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Clin Cardiol. 2019 May;42(5):572-578
pubmed: 30907012
Catheter Cardiovasc Interv. 2013 Jul 1;82(1):E1-27
pubmed: 23299937
Am J Cardiol. 2012 May 15;109(10):1431-8
pubmed: 22356795
Heart Vessels. 2016 Sep;31(9):1456-66
pubmed: 26498756
Circulation. 2004 Oct 19;110(16):2342-8
pubmed: 15477399
Catheter Cardiovasc Interv. 2015 Feb 15;85(3):335-42
pubmed: 25130788
Atherosclerosis. 2009 Dec;207(2):552-8
pubmed: 19523634
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Am Soc Nephrol. 2011 Jan;22(1):147-55
pubmed: 21164029
JAMA. 2005 Jun 15;293(23):2865-72
pubmed: 15956631
Atherosclerosis. 2011 Jun;216(2):440-5
pubmed: 21388623
Int J Clin Exp Med. 2015 Nov 15;8(11):20540-7
pubmed: 26884971
Circulation. 2008 Jan 15;117(2):296-329
pubmed: 18071078
J Clin Invest. 2013 Jan;123(1):92-100
pubmed: 23281415
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Angiology. 2015 Aug;66(7):644-51
pubmed: 25124682
Am J Kidney Dis. 2002 Aug;40(2):221-6
pubmed: 12148093
Clin Cardiol. 2009 Nov;32(11):644-8
pubmed: 19938052
Heart Vessels. 2014 Jul;29(4):429-36
pubmed: 23807612
Cardiol Res. 2015 Feb;6(1):226-231
pubmed: 28197230
Clin Cardiol. 2015 Feb;38(2):82-91
pubmed: 25649130
Clin Res Cardiol. 2011 Nov;100(11):1037-43
pubmed: 21710343
J Am Coll Cardiol. 2010 Apr 20;55(16):1649-60
pubmed: 20394867
Atherosclerosis. 2010 Mar;209(1):300-5
pubmed: 19819453
Heart Vessels. 2013 Jan;28(1):19-26
pubmed: 22160439

Auteurs

Yuewu Chen (Y)

Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.

Yan Fan (Y)

Department of Cardiovascular Medicine, Gansu Provincial Hospital, Lanzhou, China.

Min Men (M)

Department of Endocrinology, Xi'an Central Hospital, Xi'an, China.

Guidong Shen (G)

Department of Cardiovascular Medicine, Ankang Central Hospital, AnKang, China.

Aiqun Ma (A)

Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH